My NCBI | Sign In
RSS Settings
  • Search: Degn KB[au]

Display Settings:

Format
Sort by

Send to:

Choose Destination

    Results: 3

    1.

    Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia.

    Degn KB, Brock B, Juhl CB, Djurhuus CB, Grubert J, Kim D, Han J, Taylor K, Fineman M, Schmitz O.

    Diabetes. 2004 Sep;53(9):2397-403.PMID: 15331551 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

    Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O.

    Diabetes. 2004 May;53(5):1187-94.PMID: 15111485 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    The insulin secretagogues glibenclamide and repaglinide do not influence growth hormone secretion in humans but stimulate glucagon secretion during profound insulin deficiency.

    Østergård T, Degn KB, Gall MA, Carr RD, Veldhuis JD, Thomsen MK, Rizza RA, Schmitz O.

    J Clin Endocrinol Metab. 2004 Jan;89(1):297-302.PMID: 14715864 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Search details

    » See more...

    Recent activity